Ming Jin, Hongqi Lin, Lin Qiu, Hongdang Xu, Haoran Zhang, Shuhui Hou
{"title":"雷马唑仑用于左至右分流先天性心脏病患儿的成功镇静：一项上下顺序分配试验。","authors":"Ming Jin, Hongqi Lin, Lin Qiu, Hongdang Xu, Haoran Zhang, Shuhui Hou","doi":"10.1097/EJA.0000000000002183","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The findings of this study offer insights into the utilisation of remimazolam for sedation in paediatric patients with left-to-right shunt congenital heart disease (CHD).</p><p><strong>Objective: </strong>To study the median effective dose (ED 50 ) and 95 percentile of the effective dose (ED 95 ) of remimazolam for successful sedation in children with CHD.</p><p><strong>Design: </strong>A nonrandomised, nonblinded study based on the Dixon sequential method.</p><p><strong>Setting: </strong>Tertiary hospitals in Zhengzhou, Henan Province, study dates: 20 October 2023 to 18 May 2024.</p><p><strong>Patients: </strong>A total of 78 patients, comprising 32 males and 45 females, successfully completed the study. They were selected based on the following criteria: children aged 1 to 6 years with left-to-right shunt CHD; ASA physical status II-III. The key exclusion criteria were: history of allergy to sedative drugs; administration of sedative medications other than the study drug before surgery; severe pre-operative liver or kidney dysfunction; pre-operative bradycardia; and severe pre-operative respiratory diseases.</p><p><strong>Intervention: </strong>The sedation status of the patients was observed for 5 min after intravenous administration of different doses of remimazolam.</p><p><strong>Main outcome measures: </strong>The ED 50 and ED 95 of remimazolam for successful sedation in children with CHD.</p><p><strong>Results: </strong>The ED 50 (95% CI) of remimazolam for successful sedation in infants, toddlers and preschool children with CHD were 0.209 (0.184 to 0.234) mg kg -1 , 0.259 (0.234 to 0.284) mg kg -1 and 0.266 (0.207 to 0.325) mg kg -1 , respectively. ED 95 (95% CI) were 0.356 (0.282 to 0.672) mg kg -1 , 0.404 (0.330 to 0.741) mg kg -1 and 0.408 (0.334 to 0.752) mg kg -1 , respectively. No serious adverse reactions were observed with intravenous remimazolam.</p><p><strong>Conclusion: </strong>This study explored the ED 50 and ED 95 of remimazolam for pre-operative sedation in children with left-to-right shunt CHD. It provides guidance for pre-operative sedation medication in children with left-to-right shunt CHD.</p><p><strong>Trial registration: </strong>https://www.chictr.org.cn/Identifier: ChiCTR2300076458.</p>","PeriodicalId":11920,"journal":{"name":"European Journal of Anaesthesiology","volume":" ","pages":"697-703"},"PeriodicalIF":6.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237128/pdf/","citationCount":"0","resultStr":"{\"title\":\"Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease: An up-and-down sequential allocation trial.\",\"authors\":\"Ming Jin, Hongqi Lin, Lin Qiu, Hongdang Xu, Haoran Zhang, Shuhui Hou\",\"doi\":\"10.1097/EJA.0000000000002183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The findings of this study offer insights into the utilisation of remimazolam for sedation in paediatric patients with left-to-right shunt congenital heart disease (CHD).</p><p><strong>Objective: </strong>To study the median effective dose (ED 50 ) and 95 percentile of the effective dose (ED 95 ) of remimazolam for successful sedation in children with CHD.</p><p><strong>Design: </strong>A nonrandomised, nonblinded study based on the Dixon sequential method.</p><p><strong>Setting: </strong>Tertiary hospitals in Zhengzhou, Henan Province, study dates: 20 October 2023 to 18 May 2024.</p><p><strong>Patients: </strong>A total of 78 patients, comprising 32 males and 45 females, successfully completed the study. They were selected based on the following criteria: children aged 1 to 6 years with left-to-right shunt CHD; ASA physical status II-III. The key exclusion criteria were: history of allergy to sedative drugs; administration of sedative medications other than the study drug before surgery; severe pre-operative liver or kidney dysfunction; pre-operative bradycardia; and severe pre-operative respiratory diseases.</p><p><strong>Intervention: </strong>The sedation status of the patients was observed for 5 min after intravenous administration of different doses of remimazolam.</p><p><strong>Main outcome measures: </strong>The ED 50 and ED 95 of remimazolam for successful sedation in children with CHD.</p><p><strong>Results: </strong>The ED 50 (95% CI) of remimazolam for successful sedation in infants, toddlers and preschool children with CHD were 0.209 (0.184 to 0.234) mg kg -1 , 0.259 (0.234 to 0.284) mg kg -1 and 0.266 (0.207 to 0.325) mg kg -1 , respectively. ED 95 (95% CI) were 0.356 (0.282 to 0.672) mg kg -1 , 0.404 (0.330 to 0.741) mg kg -1 and 0.408 (0.334 to 0.752) mg kg -1 , respectively. No serious adverse reactions were observed with intravenous remimazolam.</p><p><strong>Conclusion: </strong>This study explored the ED 50 and ED 95 of remimazolam for pre-operative sedation in children with left-to-right shunt CHD. It provides guidance for pre-operative sedation medication in children with left-to-right shunt CHD.</p><p><strong>Trial registration: </strong>https://www.chictr.org.cn/Identifier: ChiCTR2300076458.</p>\",\"PeriodicalId\":11920,\"journal\":{\"name\":\"European Journal of Anaesthesiology\",\"volume\":\" \",\"pages\":\"697-703\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237128/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Anaesthesiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/EJA.0000000000002183\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Anaesthesiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/EJA.0000000000002183","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease: An up-and-down sequential allocation trial.
Background: The findings of this study offer insights into the utilisation of remimazolam for sedation in paediatric patients with left-to-right shunt congenital heart disease (CHD).
Objective: To study the median effective dose (ED 50 ) and 95 percentile of the effective dose (ED 95 ) of remimazolam for successful sedation in children with CHD.
Design: A nonrandomised, nonblinded study based on the Dixon sequential method.
Setting: Tertiary hospitals in Zhengzhou, Henan Province, study dates: 20 October 2023 to 18 May 2024.
Patients: A total of 78 patients, comprising 32 males and 45 females, successfully completed the study. They were selected based on the following criteria: children aged 1 to 6 years with left-to-right shunt CHD; ASA physical status II-III. The key exclusion criteria were: history of allergy to sedative drugs; administration of sedative medications other than the study drug before surgery; severe pre-operative liver or kidney dysfunction; pre-operative bradycardia; and severe pre-operative respiratory diseases.
Intervention: The sedation status of the patients was observed for 5 min after intravenous administration of different doses of remimazolam.
Main outcome measures: The ED 50 and ED 95 of remimazolam for successful sedation in children with CHD.
Results: The ED 50 (95% CI) of remimazolam for successful sedation in infants, toddlers and preschool children with CHD were 0.209 (0.184 to 0.234) mg kg -1 , 0.259 (0.234 to 0.284) mg kg -1 and 0.266 (0.207 to 0.325) mg kg -1 , respectively. ED 95 (95% CI) were 0.356 (0.282 to 0.672) mg kg -1 , 0.404 (0.330 to 0.741) mg kg -1 and 0.408 (0.334 to 0.752) mg kg -1 , respectively. No serious adverse reactions were observed with intravenous remimazolam.
Conclusion: This study explored the ED 50 and ED 95 of remimazolam for pre-operative sedation in children with left-to-right shunt CHD. It provides guidance for pre-operative sedation medication in children with left-to-right shunt CHD.
期刊介绍：
The European Journal of Anaesthesiology (EJA) publishes original work of high scientific quality in the field of anaesthesiology, pain, emergency medicine and intensive care. Preference is given to experimental work or clinical observation in man, and to laboratory work of clinical relevance. The journal also publishes commissioned reviews by an authority, editorials, invited commentaries, special articles, pro and con debates, and short reports (correspondences, case reports, short reports of clinical studies).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
